Why We Need Open Source Pharma
BY TOMASZ SABLINSKI

• current model is broken 
• fantastic progress in science has not led to enough new medications
• societal changes lead to much more open communication
• open source has proven successful in other areas of knowledge economy
• open source is consistent with virtual company model - increasingly popular
• individuals are engaged by intellectual challenge rather than financial reward
• financial reward to individuals based on outcome judged by peers
• low fixed cost
• most time spent on content rather than context and politics

Tomasz Sablinski is the CEO of Transparency Life Sciences. He is @TSablinski on Twitter.
​

---

Back

​
Other essays in this series:

​James Kassaga Arinaitwe, Global Health Corps & Aspen Institute Fellow / Kampala
Manica Balasegaram, Exec. Director, Access Campaign, Médecins Sans Frontières / Geneva
Polly J. Price, Emory University law professor / Atlanta​
John Wilbanks, Chief Commons Officer, Sage Bionetworks / Washington, D.C.
Dimitrios Tzalis, Founder & CEO, Taros Chemicals GmbH & Co. KG. / Dortmund
T.V. Mohandas Pai, Chairman, Manipal Global Education Services / Bangalore
Els Torreele, Director, Access to Essential Medicines Initiative, Open Society Foundations / NYC
​Zakir Thomas, Open innovation expert & former Project Director of OSDD / Delhi
Matthew Todd, Founder of Open Source Malaria / Sydney & Cambridge